Merck is a large pharma headquartered in US. Over the past three years, Merck has been involved in 35 licensing and acquisition transactions, with a primary focus on Small Molecules (20 deals). The company currently has 50 active clinical trials, primarily in Oncology.
Deals (12mo)
5
Active Trials
50
Top Modality
Small Molecules
Focus Area
Oncology
Licensing, acquisition, and partnership transactions involving Merck in the past 12 months.
| Asset |
|---|
| Partner |
|---|
| Modality |
|---|
| Phase |
|---|
| Type |
|---|
| Date |
|---|
| Lynparza | AstraZeneca | Small Molecules | Approved | co development | Jul 20, 2026 |
| HRS-5346 | Hengrui | Small Molecules | Phase 2 | license | Jul 18, 2026 |
| HS-10535 | Hansoh Pharma | Small Molecules | Unknown | license | Jul 1, 2026 |
| HRS-5346 | Hengrui | Small Molecules | Unknown | license | Jul 1, 2026 |
| Terns Pharmaceuticals (including TERN-701) | Merck & Co. | Small Molecules | Unknown | acquisition | Jun 14, 2026 |
| ensifentrine | Merck & Co. | Small Molecules | Approved | acquisition | Jun 14, 2026 |
| CML asset | Orna Therapeutics | mRNA | Unknown | license | Jun 9, 2026 |
| Verona Pharma pipeline | Verona Pharma | Small Molecules | Unknown | acquisition | May 18, 2026 |
| Terns Pharmaceuticals pipeline | Terns Pharmaceuticals | Small Molecules | Unknown | acquisition | May 18, 2026 |
| CML-related oncology program | Merck & Co. | Other | Unknown | license | May 15, 2026 |
Showing 10 of 16 recent transactions. Upgrade to Pro for full deal history with financials.
Therapeutic areas and modalities where Merck is most active based on deal history and clinical trial data.
Key indicators of Merck's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
Merck has 50 active clinical trials across 5 development phases.
3
Phase 4
3
Not Applicable
23
Phase 1
13
Phase 2
8
Phase 3
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Merck is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 35 deals over the past three years, Merck ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Merck include Oncology (19 deals and trials), Solid Tumors (18 deals and trials), Codev Deals (4 deals and trials), and Mega Deals (4 deals and trials). In terms of modality, Merck has shown particular interest in small molecules, other, antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Merck and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Merck's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,600+ real biopharma licensing deals